Zhou Yong, Zhu Youming, Zhang Li, Wu Tao, Wu Tingting, Zhang Wenjie, Decker Ann Marie, He Jiacai, Liu Jie, Wu Yiqun, Jiang Xinqun, Zhang Zhiyuan, Liang Chaozhao, Zou Duohong
Department of Dental Implant Center, Stomatologic Hospital & College, Anhui Medical University, Key Laboratory of Oral Diseases Research of Anhui Province, Hefei, PR, China.
Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, PR, China.
Stem Cells. 2016 Apr;34(4):924-34. doi: 10.1002/stem.2321. Epub 2016 Feb 24.
Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities. However, the effective and optimal treatment for CLI remains to be elucidated. Previous therapeutic research is mainly focused on proangiogenic growth factors administrations. Recently, miR-21 has been revealed to play a crucial role in angiogenesis. Thus, we hypothesize that miR-21 over-expression in human umbilical cord blood-derived mesenchymal stem cells (UCBMSCs) can effectively treat CLI. Herein, UCBMSCs were transduced with lentivirus-miR-21-Luciferase (Lenti-miR-21) or lentivirus- LacZ-Luciferase (Lenti-LacZ). The results indicated that miR-21 induced UCBMSCs proliferation, migration, and angiogenesis in vitro. Subsequently, general observation and laser Doppler perfusion imaging were introduced to detect perfusion in muscles of CLI-nude mice on 1, 4, 7, 14, and 28 day postoperation. There was a significant improvement in blood vessels of the ischemic limb in Lenti-miR-21 group at 7 day compared with the saline or Lenti-LacZ groups. At 28 day, histological analysis confirmed that UCBMSCs over-expressing miR-21 increased neovascularization in CLI. Furthermore, carboxyl terminus of Hsc70-interacting protein (CHIP) was found to be the target gene for miR-21-mediated activation of hypoxia-inducible factor 1α (HIF-1α) in UCBMSCs. In summary, our study demonstrated that over-expressing miR-21 in UCBMSCs could improve neovascularization in CLI through enhancing HIF-1α activity by targeting CHIP, which may hold great therapeutic promise in treating CLI.
严重肢体缺血(CLI)是下肢动脉的严重阻塞。然而,CLI的有效和最佳治疗方法仍有待阐明。以往的治疗研究主要集中在促血管生成生长因子的应用上。最近,miR-21已被证明在血管生成中起关键作用。因此,我们假设人脐带血来源的间充质干细胞(UCBMSC)中miR-21的过表达可以有效治疗CLI。在此,用慢病毒-miR-21-荧光素酶(Lenti-miR-21)或慢病毒-LacZ-荧光素酶(Lenti-LacZ)转导UCBMSC。结果表明,miR-21在体外诱导UCBMSC增殖、迁移和血管生成。随后,采用大体观察和激光多普勒灌注成像检测CLI裸鼠术后1、4、7、14和28天肌肉的灌注情况。与生理盐水或Lenti-LacZ组相比,Lenti-miR-21组在术后7天时缺血肢体血管有显著改善。在术后28天时,组织学分析证实过表达miR-21的UCBMSC增加了CLI中的新生血管形成。此外,发现热休克蛋白70相互作用蛋白(CHIP)的羧基末端是miR-21介导的UCBMSC中缺氧诱导因子1α(HIF-1α)激活的靶基因。总之,我们的研究表明,UCBMSC中miR-21的过表达可通过靶向CHIP增强HIF-1α活性来改善CLI中的新生血管形成,这可能在治疗CLI方面具有巨大的治疗前景。